The nutrition company says it will invest in research and clinical trials as it reports a ₹52 crore annualised revenue run rate at the end of FY26.
Mumbai-based nutrition company Ace Blend has announced a $9.91 million Series A2 funding round led by 3one4 Capital, with existing investor Fireside Ventures participating again, according to the company.
The company says it will use the proceeds to expand research and development, strengthen quality testing and develop new product formats. It has not disclosed the round’s valuation or a detailed allocation of the funds.
Ace Blend reported FY25 revenue of approximately ₹12.6 crore, according to secondary financial data for Aces Intact Private Limited, the entity associated with the brand. The company says it ended FY26 with an annualised revenue run rate of ₹52 crore. This represents an extrapolation of its business pace at the end of the financial year, not confirmed revenue earned during the full year.
The funding announcement and the company’s latest revenue run rate have not been independently confirmed by the investors or through audited FY26 financial statements.
Core products and distribution
Founded by Shivam Hingorani, Ace Blend sells nutritional supplements, including omega-3, magnesium and multivitamins. Saif Mehkri joined as co-founder in 2022.
The company attributes its growth to demand for its products and expansion beyond its own website to marketplaces such as Amazon and quick-commerce platforms. It has not disclosed revenue by product or sales channel.
Ace Blend says returning customers account for 45%–48% of monthly revenue on its direct-to-consumer channel. This is a revenue-share metric, not the percentage of customers who make repeat purchases. The company says the share has remained within this range as it has acquired new customers. The calculation and underlying data have not been independently verified.
Research and product development
Ace Blend describes its approach as science-led and says it works with international ingredient suppliers, including dsm-firmenich. The company also claims exclusive rights in India’s direct-to-consumer market for products built around the supplier’s life’sOMEGA technology. The scope and duration of those rights have not been independently established.
The company says its formulations draw on pharmacokinetic data and that it plans to use the new funding to support clinical trials through a contract research organisation. It intends to seek publication of the findings in international journals. The status of the trials and their protocols were not independently confirmed for this report.
Evidence supporting an ingredient does not, by itself, establish the clinical efficacy of a finished supplement. Results from appropriately designed studies of the finished formulation would be needed to assess product-specific claims.
Ace Blend also says it received a patent in July 2026 for a product format planned for launch in the fourth quarter of FY27. The patent number and grant details were not independently verified at the time of publication.
Profitability remains ahead
Ace Blend says it expects to reach profitability within 18–24 months. It attributes its current spending to operating costs, team expansion and infrastructure developed in anticipation of growth. The company has not specified whether its target refers to EBITDA, operating profit or net profit.
Secondary financial data for Aces Intact Private Limited records a net loss of approximately ₹7.64 crore and negative EBITDA of ₹7.07 crore in FY25. These historical figures provide context for the company’s stated profitability target but do not establish its current financial position.
The company’s ability to meet that target will depend on revenue growth, margins, customer acquisition costs and operating expenditure. It has not disclosed a detailed profitability roadmap.
Investors’ rationale
3one4 Capital cited Ace Blend’s formulations, manufacturing operations and approach to ingredient sourcing in explaining its investment.
“Ace Blend is tackling the hardest problems in nutrition: innovating new formulations for the Indian context, repeatably delivering quality and consistency, and earning consumer trust, as a unified and vertically integrated platform. In a crowded category where low-moat brands behave like traders and compete only on marketing, Ace is scaling science-led formulations and a trust-first approach with rigorous focus on ingredient quality, sourcing discipline, and manufacturing specialisation. That foundation gives the company control over quality and claims, more depth to innovate, and an efficiency advantage that is difficult to reproduce. We believe this is an opportunity to scale a durable Indian consumer-health innovator, and we’re excited to partner with this team to help deliver that potential,” said Pranav Pai, Managing Partner, 3one4 Capital.
Fireside Ventures, an earlier investor in Ace Blend, is participating in the latest round, according to the company.
“What stood out to us about Ace Blend was the team’s ability to identify unmet needs in Indian nutrition early and address them with high-efficacy, science built products. Their deep R&D capabilities and vertically integrated operations provide a strong foundation for continued innovation. The team’s clinical credibility is further reinforced by its exclusive partnerships with leading global ingredient suppliers. But the strongest validation comes from consumers themselves; high repeat rates and positive word of mouth reflect the trust the brand has earned. We’re delighted to double down and back Shivam, Saif and the team as they build Ace Blend into a leading Indian nutrition brand,” said Ankita Balotia, Principal, Fireside Ventures.
The new funding is intended to support Ace Blend’s research and product development plans. Whether the investment translates into sustained growth and profitability will become clearer as the company reports subsequent financial results.
Editorial note: FY25 financial figures are based on secondary financial data. The funding terms, FY26 annualised revenue run rate, repeat-revenue metric, exclusivity rights, patent details and forward-looking plans are attributed to the company or its representatives where independent confirmation was unavailable. Investor quotations should be checked against the original approved statements before publication.
Also Read:Beyond Valuation Trap: How Zorko Built a 500-Outlet QSR Empire on Pure Profitability
